Tag: Inventiva
Inventiva announces the filing of its 2023 Universal Registration Document and its 2023 Annual Report (“Form 20-F”) – 04/03/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the filing of its 2023 Universal Registration Document and its 2023 Annual Report (“Form 20-F”) – 04/03/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva down after widening its losses in 2023
(AOF) – Inventiva (-2.54% to 3.26 euros) is down after announcing a net loss more than doubled in 2023. The biotech specializing in the treatment of steatohepatitis associated with metabolic…
Inventiva announces the date of publication and presentation of its 2023 financial results – 03/22/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the date of publication and presentation of its 2023 financial results – 03/22/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Abnormal volumes on the Paris stock exchange: Inventiva, CGG
During this stock market session on Tuesday March 19, 2024, particularly high trading volumes were detected on the French market. Today, it is the Inventiva share which stands out, with…
Inventiva jumps after positive results from its Legend trial
(AOF) – Inventiva (+12.11% to 4.26 euros) jumps after the positive results of the Legend clinical trial combining lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes. The…
Inventiva announces positive results from the proof-of-concept Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes – 03/18/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: Lifting of the pause for the NATiV3 study
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Inventiva: lifting of the pause for the NATiV3 study – 03/08/2024 at 3:25 p.m.
(CercleFinance.com) – Inventiva announces the lifting of the previously announced voluntary pause in screening and randomization for its NATiV3 clinical study, evaluating its lanifibranor in NASH (non-alcoholic fatty liver disease)…
Inventiva: pause lifted for the NATiV3 study
(CercleFinance.com) – Inventiva announces the lifting of the previously announced voluntary pause in screening and randomization for its NATiV3 clinical study, evaluating its lanifibranor in NASH (non-alcoholic fatty liver disease)…
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…